IGM Biosciences (IGMS)

• Market cap: $77.1M
• 1 day: -7.19%
• 5 days: -5.15%
• 1 month: -5.84%
• 3 months: -82.01%
• 6 months: -89.51%
• Year to date: -79.23%
• 1 year: -87.04%
• 5 years: -96.46%
• 10 years: -94.69%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Employees: 149

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

220% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 5

68% more call options, than puts

Call options by funds: $377K | Put options by funds: $224K

37% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 19

15% more funds holding

Funds holding: 72 [Q3] → 83 (+11) [Q4]

0.07% more ownership

Funds ownership: 63.54% [Q3] → 63.61% (+0.07%) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

63% less capital invested

Capital invested by funds: $357M [Q3] → $133M (-$224M) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.50 16% upside
• Avg. target: $2 55% upside
• High target: $2.50 94% upside

5 analyst ratings

• positive: 0 0%
• neutral: 5 100%
• negative: 0 0%

Jefferies Roger Song 24% 1-year accuracy 4 / 17 met price target	55% upside $2	Hold Downgraded	10 Jan 2025
Truist Securities Asthika Goonewardene 28% 1-year accuracy 7 / 25 met price target	55% upside $2	Hold Maintained	10 Jan 2025
Stifel Stephen Willey 26% 1-year accuracy 5 / 19 met price target	94% upside $2.50	Hold Downgraded	10 Jan 2025
RBC Capital Brian Abrahams 15% 1-year accuracy 11 / 71 met price target	16% upside $1.50	Sector Perform Downgraded	10 Jan 2025
BMO Capital Etzer Darout 28% 1-year accuracy 10 / 36 met price target	55% upside $2	Market Perform Downgraded	10 Jan 2025